Ovarian Cancer New Drug: Mirvetuximab Soravtansine in FRalpha Positive Ovarian Cancer Ulas D. Bayraktar, MD 2023-01-10
Melanoma New Protocol: Atezolizumab with Vemurafenib and Cobimetinib in Metastatic Melanoma Ulas D. Bayraktar, MD 2023-01-10
Chronic Lymphocytic Leukemia New Reference: Zanubrutinib for R/R CLL Ulas D. Bayraktar, MD 2023-01-10
Breast Cancer New Reference: Pembrolizumab in Triple-Negative Breast Cancer Ulas D. Bayraktar, MD 2022-11-26
Hepatocellular Carcinoma New Reference: Cabozantinib and Atezolizumab in HCC Ulas D. Bayraktar, MD 2022-11-26
Hodgkin Lymphoma New Reference: Bretuximab Vedotin in Stage III-IV Hdogkin Lymphoma Ulas D. Bayraktar, MD 2022-11-26
Breast Cancer New Protocol: Pembrolizumab with Chemotherapy in Triple-Negative Breast Cancer Ulas D. Bayraktar, MD 2022-11-26
